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Background: While electronic cigarettes are forbidden in several countries, their sales are exploding in many
others. Although e-cigarettes have been proposed as long-term substitutes for traditional smoking or as a tool for
smoking cessation, very scarce data are available on their efficacy and safety.
We describe the protocol of a 5-year multicentric prospective study aimed to evaluate short- and long-term
adherence to e-cigarette smoking and the efficacy of e-cigarettes in reducing and/or quitting traditional cigarette
smoking. The study will also compare the health effects of electronic vs traditional vs mixed cigarette smoking.
Methods/design: From June to December 2013, we will enroll adult smokers of: (EC) e-cigarettes (self-reported
inhaling ≥ 50 puffs per week since ≥ 6 months); (TC) traditional cigarettes (≥ 1 per day since ≥ 6 m); (Mixed) both
electronic and traditional cigarettes (≥1 per day since ≥ 6 m). Eligible subjects will be requested participation
through newspaper advertisements and direct contact at the shops. Each subject will have to compile a structured
questionnaire at enrolment and after 6, 12, 24, 36 and 60 months. The level of carbon monoxide in expired after
breath will be evaluated in all subjects declaring no traditional cigarette smoking in any follow-up phase, using
portable carbon monoxide analyzers. The primary outcomes are traditional smoking cessation rates and number of
smoked cigarettes. Secondary outcomes include adherence to e-cigarettes, self-reported adverse events, quality of
life, and time to hospital admission for one among cardiovascular diseases, chronic obstructive pulmonary diseases,
cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia.
Admissions will be checked using official discharge data of the Abruzzo Region. A minimum of 500 subjects in each
group will be enrolled, for a total of 1500 participants. Cox proportional hazards analysis will be used to calculate
adjusted relative hazards of smoking cessation by each variable.
Discussion: Data on long-term efficacy and safety of e-cigarettes will be of utmost importance to form the basis
for guidelines and regulatory decisions on e-cigarettes.
Trial registration: The protocol has been registered (NCT01785537) and approved by the Ethics Committee of the
University of Chieti (Record n. 6; 25-03-2013).
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The electronic cigarette (e-cigarette) market has been
exploding over the past few years, reaching an estimated
$500 millions during 2012 in USA; an expected $1 billions
by the end of 2013 [1,2]; and achieving similar growth
in some European countries [3,4]. Indeed, people report
buying e-cigarettes to help quit smoking, to reduce
cigarette consumption, to relieve tobacco withdrawal
symptoms due to workplace smoking restrictions and
to continue to have a ‘smoking’ experience but with
reduced health risks [5]. As a matter of fact, e-cigarette
is becoming a social phenomenon of global proportion
[6,7], which calls for research, legislation and product
development [8,9].
Although the product has been proposed as a long-
term substitute for traditional smoking or as a tool for
smoking cessation [10,11], some authorities are opposing
the recreational use of nicotine because there are
concerns about both safety and efficacy, and about the
potential risk of e-cigarettes to play as a promoter of
smoking for never or ex-smokers [10,12-14]. In fact, the
sale of e-cigarettes market is subject to limitations in many
countries (i.e. USA and Germany) and is forbidden in
several others (i.e. China, Brazil) [14].
To date, twelve studies were started evaluating the
acceptability, safety or efficacy of e-cigarettes containing
nicotine [5,15-25]; seven were completed [16-21,24],
and only four have been published [16,17,24,26]. Al-
though the results are encouraging, they are based
upon a total sample of <300 subjects, who were
followed for no more than 6 months. No data are
available on long-term efficacy and safety and, most
importantly, no ongoing study has been designed to
collect data on hard outcomes (smoking-related cancer,
major cardiovascular events and chronic obstructive
pulmonary disease – COPD) over a long follow-up
period [11,24].
The main aims of the study are to evaluate for
the first time the long-term adherence to e-cigarette
smoking and the efficacy of e-cigarettes in reducing
and/or quitting traditional cigarette smoking. As
secondary aims, the study will also evaluate the long-
term safety (in terms of smoking-related serious
diseases requiring hospitalization) of e-cigarette smok-
ing, comparing its health effects with those of trad-
itional cigarette smoking and mixed electronic and
traditional cigarette smoking. We will evaluate over a
5-year follow-up the number of smoking-related hospi-
talizations, the self-reported quality of life, and the
reported adverse events according to current and past
smoking habit.
The present paper describes the research proto-
col of the project, which is currently on course
(NCT01785537).Methods/design
Study design and population
This is an observational, prospective cohort study. None
of the participants will receive an indication about which
product to smoke. In fact, all participants will receive
structured flyers reporting the main harms of cigarette
smoking.
An individual will be considered for participation if:
– resident in Italy;
– aged between 30 and 75 years;
– smoker of e-cigarettes (inhaling at least 50 puffs per
week) since six or more months (EC Group);
– smoker of at least one traditional cigarette per day
since six or more months (TC Group);
– smoker of both electronic and traditional cigarettes
(at least one per day) since six or more months
(Mixed Group).
Exclusion criteria will be:
– illicit drug use,
– breastfeeding or pregnancy,
– major depression or other psychiatric conditions,
– severe allergies,
– active antihypertensive medication,
– angina pectoris,
– past episodes of selected smoking-related major
diseases (myocardial infarction, stroke/TIA,
congestive heart failure, COPD, cancer of the lung,
esophagus, larynx, oral cavity, bladder, pancreas,
kidney, stomach, cervix, and myeloid leukemia).
Potentially eligible subjects will be requested participa-
tion through newspaper and internet advertisements,
through direct contact with an investigator at the shops,
finally through direct contact with some of the general
practitioners of the Abruzzo Section of the Italian Scien-
tific Society of General Medicine (SIMG) who voluntar-
ily participate to the project. Specific agreements will
be established with the sellers to permit the presence of an
investigator during conventional working hours. Inclusion
and exclusion criteria will be self-reported and further
verified by the investigator in case of participation.
The enrolment period will last from June to December
2013. Each subject will be requested to compile a struc-
tured questionnaire at the time of enrolment at after 6,
12, 24, 36 and 60 months (and eventually, in the case of
an expansion of the follow-up, at 84 and 120 months).
After the first contact, the follow-up questionnaires will
be compiled through a phone interview or through a
specifically created website (http://www.ipazienti/fumo),
with private password. To reduce potential misclassifi-
cation, the level of carbon monoxide in expired after
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itional cigarette smoking in any phase of the follow-up,
using portable carbon monoxide analyzers (Smokerlyzer ®
piCO + ™, Bedfont Scientific Ltd.). Such an assessment
will be made by the investigators, after specific period-
ical calibration, directly at the home of the participant
or at the office of his/her general practitioner. Among
the methods to monitor self-reported smoking cessation,
also the assessment of cotinine in saliva can be made using
portable and relatively economical devices, and such test
showed a slightly higher sensitivity/specificity than tests
based upon exhaled CO [27]. However, we were not able
to find a seller of cotinine portable tests on saliva, and
the measurement of breath CO still showed high levels
of sensitivity (>90% [27,28]).
Each participant will have to sign a written informed
consent. The study protocol has been registered in
Clinicaltrials.gov (NCT01785537) and approved by the
Ethics Committee of the University of Chieti (Record n.
6; 25-03-2013).
Participants will be enrolled at various study sites
within the Abruzzo and Lazio Region using the same
standardized procedures.
All the subjects that will be excluded because of past
episodes of selected smoking-related major diseases will
be requested to participate into a nested case–control
pilot study, in which we will collect hospital admission
data retrospectively and compare the rates of smoking-
related diseases according to the present and past smok-
ing habits.
Interventions and groups
This is a non-interventional observational study. The
participants will be divided into three cohorts/groups
according to their self-determined smoking pattern:
– Group EC - smokers of e-cigarettes only (who are
not smoking traditional cigarettes). This group will
be further split in the analysis: never or former
smokers of traditional cigarettes; smokers of
e-cigarettes with or without nicotine.
– Group TC - smokers of traditional cigarettes only.
This group will be further split in the analysis:
recent and older smokers.
– Mixed Group - smokers of both traditional and
electronic cigarettes. This group will be further split
in the analysis: mixed smokers who quit and who
did not quit traditional cigarette smoking during
follow-up.
Questionnaire
The structured questionnaire is available as online sup-
plementary material and contains questions on demo-
graphic data (gender, age, height and weight, educationallevel, marital status, occupation), previous diseases which
are and are not among the reasons for the exclusion,
smoking habits, smoking related diseases which did or
did not require hospitalizations (only in follow-up as-
sessments), lifestyle behavior (physical activity, alcohol
use) and quality of life. The latter issue will be investi-
gated using the Italian version of the validated EuroQol
EQ-D5L questionnaire [29]. The questionnaire will be
kept as short as possible to allow phone interviews and
will be initially tested on a sample of 50 participants to
assess acceptability, exclude potentially redundant or
include potentially useful questions.
Primary outcomes
1. Traditional smoking cessation: percentage of
subjects that were current (in TC and Mixed
groups) or former (in EC group) smokers reporting
sustained smoking abstinence from traditional
cigarette smoking at 6, 12, 24, 36 and 60 months.
Smoking abstinence is defined as complete
abstinence from tobacco smoking (not even a puff )
for the 30 days period prior to the visit.
2. Decrease in the number of traditional cigarettes
smoked: average difference in self-reported number
of traditional cigarettes smoked per day at baseline
and 6, 12, 24, 36 and 60 months in the groups TC
and Mixed.
Secondary outcomes
1. Adherence to e-cigarette smoking: number of
months of continued e-cigarette smoking in groups
EC and Mixed.
2. Traditional and electronic smoking (overall
smoking) cessation: percentage of subjects in all
groups reporting sustained smoking abstinence from
both traditional and electronic cigarette smoking at
6, 12, 24, 36 and 60 months. Smoking abstinence is
defined as complete abstinence from tobacco or
electronic smoking (not even a puff ) for the 30 days
period prior to the visit.
3. Time to hospital admission for one of the followings:
cardiovascular diseases, chronic obstructive
pulmonary diseases, cancer of the lung, esophagus,
larynx, oral cavity, bladder, pancreas, kidney,
stomach, cervix, and myeloid leukemia. Repeated
admissions of the same subject will be counted once
and the subject will be censored at the date of the
first admission.
4. Rate of subjects with smoking-related
hospitalizations: percentage at 1, 2, 3 and 5 years of
subjects who had a hospital admission for one of the
followings: cardiovascular diseases, chronic
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esophagus, larynx, oral cavity, bladder, pancreas,
kidney, stomach, cervix, and myeloid leukemia.
Repeated admissions of the same subject will be
counted once.
5. Number of smoking-related hospitalizations: mean
number at 1, 2, 3 and 5 years of hospital admissions
for one of the followings: cardiovascular diseases,
chronic obstructive pulmonary diseases, cancer of
the lung, esophagus, larynx, oral cavity, bladder,
pancreas, kidney, stomach, cervix, and myeloid
leukemia. Each admissions of the same subject will
be counted.
6. Number of hospitalizations for cardiovascular
diseases: mean number at 3 and 5 years of hospital
admissions for cardiovascular diseases. Each
admissions of the same subject will be counted.
7. Number of hospitalizations for smoking-related
cancers: mean number at 3 and 5 years of hospital
admissions for cancer of the lung, esophagus, larynx,
oral cavity, bladder, pancreas, kidney, stomach,
cervix, and myeloid leukemia. Each admissions of
the same subject will be counted.
8. Self-reported quality of life: average quality of life
according to EuroQoL EQ-5DL at 6, 12, 24 and
36 months. The analysis of quality of life will follow
the technical specifications recommended by the
EuroQol group [29].
9. Reported side effects at 6, 12, 24, 36 and 60 months.
All outcomes will be self-reported; primary outcome 1
and secondary outcome 2 will be checked using portable
CO analyzers, and secondary outcomes 3–7 will be
checked using hospital discharge abstracts through a
linkage to fiscal codes (for the residents in Abruzzo
only). The permission will be granted from each partici-
pants and hospitalization data will be provided by the
Regional Healthcare Agency of Abruzzo. The admissions
for each of the conditions included in the composite
outcomes will be defined as follows, based upon the
ICD-9-CM principal diagnosis codes in the Italian hos-
pital discharge abstracts (SDO):
– COPD or asthma - 490, 490.0, 491.1, 491.2, 491.21,
491.8, 491.9, 492.0, 492.8, 494, 494.0, 494.1, 496,
493.00, 493.01, 493.02, 493.10, 493.11, 493.12,
493.20, 493.21, 493.22, 493.81, 493.82, 493.90,
493.91, 493.92 [30]
– Myocardial infarction - 410.0-410.9
– Congestive heart failure - 428.0-428.9
– Transitory cerebrovascular ischemia - 435.0-435.9
– Stroke - 433.0-434.9
– Cancer of the lung - 162.0-162.9
– Cancer of the esophagus - 150.0-150.9– Cancer of the larynx - 161.0-161.9
– Cancer of the oral cavity - 140.0-149.9
– Cancer of the bladder - 188.0-188.9
– Cancer of the pancreas - 157.0-157.9
– Cancer of the kidney - 189.0
– Cancer of the, stomach - 151.0-151.9
– Cancer of the cervix - 180.0-180.9
– Myeloid leukemia - 205.0-205.9
Sample size estimation
The primary analyses will compare: (A) the primary out-
come 1 (rate of traditional smoking sustained cessation)
across the groups TC, Mixed and EC (only the subjects
that were former traditional smokers); (B) the difference
in the number of traditional cigarettes smoked per day
between baseline and end of follow-up in groups TC
and Mixed.
As regards primary analysis 1, conservatively assuming
a 5-year cessation rate of 20% in the TC group, and 30%
in the Mixed group (EC group most probably having a
higher cessation rate), we would need 313 subjects per
group to achieve a power of 80%. Given the need of
multivariate modeling and an expected 20% rate of with-
drawals/dropouts, 500 subjects would be required in
each group.
Concerning primary analysis 2, assuming a 5-year re-
duction in the number of smoked traditional cigarettes
of 2 ± 6 and 4 ± 6 in the Mixed group, with the same
above parameters (alpha error = 0.05; beta-error = 0.20;
dropout/withdrawals = 20%), we would only require 240
subjects per group.
We will thus conservatively enroll a minimum of 500
subjects in each group (EC, TC and Mixed), for a total
of 1500 participants.
Data analysis
All data will be collected and initially handled by the Co-
ordinating unit, which is responsible for privacy regula-
tions and maintains the property.
At each time-point, the differences in the rates of trad-
itional smoking cessation (or other categorical outcomes
such as adverse events) across groups will be first exam-
ined using Fisher’s exact test. Cox proportional hazards
analysis will be used to calculate the adjusted relative
hazards of traditional smoking cessation (and smoking-
related hospitalization) by each variable. Stochastic level
of entry into the model will be set at 0.10, with age, gender,
and smoking groups forced to entry, and multicollinearity,
interactions with time to event and higher-power terms will
be explored for all variables in the final model. A minimum
events-to-variable ratio of 10 will be maintained in multi-
variate modeling to avoid overfitting, and Schoenfeld’s test
will be performed to check the validity of proportional
hazards assumption. Kaplan-Meier survival analysis will
Manzoli et al. BMC Public Health 2013, 13:883 Page 5 of 6
http://www.biomedcentral.com/1471-2458/13/883also be used to examine the association between hos-
pitalization and smoking group. The validity of constant
incidence ratios over the follow-up will be checked using
Nelson-Aalen cumulative hazard estimates.
Multiple linear regression will be used to investigate the
predictors of the difference in the number of traditional
cigarettes smoked between baseline and each time-point
of follow-up. Additional multivariate models such as
mixed-effect logistic models will be explored for both
the primary and secondary outcomes to account for
repeated observations and the potential distortions of
the variability in the exposure to traditional cigarette
smoking by the participants in groups EC and Mixed
(for which also stratification will be considered) [31]. In
all mixed models, the cluster variables will be participant’s
id, nicotine level of the electronic and traditional cigarette
and exposure to past traditional cigarette smoking. We
will assume and independent correlation structure for
all clusters, but we will also repeat all models setting an
exchangeable correlation structure.
The prevalence of e-cigarette smoking compliance
(secondary outcome n. 1) will similarly be derived at 6,
12, 24, 36 and 60 months. However, with the exception
of the 6-months cut-off (which will probably include
the vast majority of participants), the crude estimates
of adherence for the following time-points would most
probably be underestimated, as several participants
who are still adherent will be excluded because they
will not be followed up to the cut-off point. Therefore,
adjusted estimates of adherence for each follow-up
point will be calculated using the Nelson-Aalen method for
censoring, which assigns censored observations according
to the corresponding period of failure incidence [32].
A p-value of <0.05 will be considered significant for all
analyses, which will be performed using STATA statis-
tical software, version 11.1 (Stata Corporation, College
Station, TX, USA, 2007).
Timetable, participating units and funding
We will start in June, 2013, and the enrolment period
will end in December 31, 2013. The preliminary data on
outcomes which do not require a first checking through
hospital discharge abstracts will thus be available by the
end of 2014. A first publication is consequently scheduled
for the second semester of 2014, and it will report also
the results of the pilot nested case–control study on the
subjects that accepted to participate but were excluded
from the prospective cohort study because of past epi-
sodes of major diseases.
Hospital discharge abstracts are typically available in
the Abruzzo region four months after the end of the year.
Thus, we plan to obtain the first data on hospitalizations
by May 2014, and to finish the data collection by May
2019. The final results of the study will therefore beavailable at the end of the first semester 2019. Eventually,
in case of funds availability and approval by the Ethics
Committee, the follow-up could be extended up to ten
years.
The following units will participate in the project:
– Department of Medicine and Aging Sciences,
University of Chieti (Coordinating unit and sponsor)
– Healthcare Professions Unit, Local Health Authority
of Lanciano-Vasto-Chieti (recruitment and
data collection)
– University of Turin (recruitment and data collection)
– University Sapienza of Rome (study design
and analyses)
– University “Catholic of the Sacred Heart” of Rome
(statistical analyses and publication support)
Other institutions and sponsors could be involved dur-
ing the course of the study. In particular, additional
sponsors will be actively searched.Discussion
While electronic cigarettes are forbidden in several coun-
tries, their sales are exploding in many others [1-3,14].
Data from multicenter prospective studies evaluating the
long-term health effects of e-cigarettes and their utility to
induce traditional smoking reduction or cessation are
strongly needed and will be of utmost importance to form
the basis for guidelines and regulatory decisions on e-
cigarettes, which may prove to be the most promising
solution for the reduction of the health damages associ-
ated with conventional smoking [10,11].
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